# Krsnaa Diagnostics share price today (Krsnaa Diagnostics Ltd, NSE: KRSNAA)

> Krsnaa Diagnostics share price today: ₹485.80 at the NSE close on 3 November 2026, down 37.5% in a year. Krsnaa Diagnostics (NSE: KRSNAA) is worth ₹1,575 crore, trades at a P/E of 16.2 and has closed between ₹485.80 and ₹816.55 over the past 52 weeks. > Krsnaa Diagnostics Ltd's P/E is near the low end of its own history, higher than only 0% of past readings, and its quarterly results are still getting worse. KRSNAA · Diagnostics · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/krsnaa-diagnostics-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: ₹485.80 (−37.5% in a year)
- P/E: 16.2× (lower than 100% of the last 4.4 years)
- Revenue (Jun 2026): ₹236 Cr (+22.3% on a year ago)
- Profit (Jun 2026): ₹17.0 Cr (−19.0% on a year ago)
- Operating margin: 25.0% (−2.0 points on a year ago)
- ROCE: 13%, FY26
- ROIC: 8.0%, against a 12.0% cost of capital: −4.0 points

The main question: yearly earnings per share moved +30.1% while the share price moved −37.5%. ## What is the Krsnaa Diagnostics share price today? Krsnaa Diagnostics Ltd's share price was ₹485.80 at the close on 3 November 2026. It has been falling for 45 weeks. That is 17.6% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹486 and ₹817, and at that close it was at the low of that range. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 1 week running. Over the last 5.2 years the share price moved −48% while the NIFTY 500 moved +55%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Krsnaa Diagnostics this quarter? Three changes stood out: revenue up on a year earlier for 11 quarters in a row (every quarter we can compare), lowest operating margin in 8 quarters and highest quarterly revenue in 15 quarters. 1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare) In the June 2026 quarter revenue was ₹236 crore, +22.3% on a year earlier. Why: Revenue rose because a big Rajasthan contract moved from setup into running services. Next results: check whether retail brings in the targeted share of group revenue. From the earnings call on 14 Aug 2026. 2. Lowest operating margin in 8 quarters Operating margin was 25% in the June 2026 quarter, against 27% a year earlier. Why: Margins fell because a big new Rajasthan contract added staff and collection costs before it brought in full revenue. Next results: check whether the retail unit stops losing money and helps margins. From the earnings call on 14 Aug 2026. 3. Highest quarterly revenue in 15 quarters Revenue of ₹236 crore in the June 2026 quarter is the highest of the last 15 quarters. ## What are Krsnaa Diagnostics' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Krsnaa Diagnostics reported revenue of ₹236 crore, up 22.3% from ₹193 crore a year earlier, and a profit of ₹17.0 crore, down 19.0% from ₹21.0 crore. ### Krsnaa Diagnostics results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹236 crore | ₹193 crore | +22.3% |
| Profit | ₹17.0 crore | ₹21.0 crore | −19.0% |
| Earnings per share | ₹5.10 | ₹6.33 | −19.4% |
| Operating margin | 25.0% | 27.0% | −2.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Krsnaa Diagnostics' management discussed these results on a call held on 14 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Krsnaa Diagnostics share price history? Krsnaa Diagnostics closed at ₹485.80 on 3 November 2026, down 37.5% from ₹776.70 a year earlier (31 October 2025) and down 27.7% over five years. Its highest weekly close since August 2021 was ₹995.55 on 29 November 2024. ### Krsnaa Diagnostics share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹498.40 | −2.5% |
| 1 month ago · 1 Oct 2026 | ₹554.85 | −12.4% |
| 6 months ago · 30 Apr 2026 | ₹588.75 | −17.5% |
| 1 year ago · 31 Oct 2025 | ₹776.70 | −37.5% |
| 3 years ago · 3 Nov 2023 | ₹718.35 | −32.4% |
| 5 years ago · 4 Nov 2021 | ₹672.25 | −27.7% |
| Earliest weekly close in our records · 20 Aug 2021 | ₹926.90 | −47.6% |
| Highest weekly close since August 2021 · 29 Nov 2024 | ₹995.55 | −51.2% |
| Lowest weekly close since August 2021 · 3 Mar 2023 | ₹361.85 | +34.3% |
| 52-week high (weekly close) · 21 Nov 2025 | ₹816.55 | −40.5% |
| 52-week low (weekly close) · 3 Nov 2026 | ₹485.80 | 0.0% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (276 weekly closes from 20 August 2021 to 3 November 2026.)

## What is the latest news on Krsnaa Diagnostics? 3 Nov 2026: Krsnaa Diagnostics closed at ₹485.80, down 2.5% on the week and down 12.4% on the month. 18 Sep 2026: ex-date for a dividend of ₹2 a share. ### Earlier

- 14 Aug 2026: Krsnaa Diagnostics held its results call for April to June 2026. Management guided: Rajasthan revenue expected to double in July to September 2026; FY27 clear visibility ₹100-150 crore and steady-state ₹150-175 crore; earlier ₹200-250 crore aspiration retained. - Results for April to June 2026: Revenue up 22.3% and profit down 19.0% on a year earlier. ## What dividend does Krsnaa Diagnostics pay? Krsnaa Diagnostics paid ₹2 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.41% at the ₹485.80 close on 3 November 2026. The last was a dividend of ₹2 a share, ex-date 18 September 2026. ### Krsnaa Diagnostics dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 18 Sep 2026 | ₹2 | Dividend | same day |
| 12 Sep 2025 | ₹2.75 | Dividend | same day |
| 13 Sep 2024 | ₹2.50 | Dividend | same day |
| 15 Sep 2023 | ₹2.75 | Dividend | same day |
| 15 Sep 2022 | ₹2.50 | Dividend | 16 Sep 2022 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 4 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Krsnaa Diagnostics Ltd paid out 6% of its profit as dividends in FY26, and it paid a dividend in 5 of its last 11 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Krsnaa Diagnostics management say on the latest results call? On the call for April to June 2026, held on 14 August 2026, Krsnaa Diagnostics' management guided: Rajasthan revenue expected to double in July to September 2026; FY27 clear visibility ₹100-150 crore and steady-state ₹150-175 crore; earlier ₹200-250 crore aspiration retained. > “From a margin perspective, once the Rajasthan operation normalizes in terms of operational maturity, we expect margins to return to double digits by the end of the year as a whole.”
> Yash Mutha, on the call for April to June 2026

### What management guided

- Retail contribution planned at 10-15% of group revenue in FY27. - RPL expected to become operating profit positive by July to September 2026. - Remaining Maharashtra MRI centers expected live by the end of October to December 2026. - Consolidated margins expected to return to double digits by year-end as Rajasthan normalizes. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/44114/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 14 August 2026.)

## What to watch in Krsnaa Diagnostics' next results? When Krsnaa Diagnostics reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Rajasthan utilization and sequential revenue ramp next quarter - check fixed-cost absorption and consolidated margin improvement. - What to check (from the call)
- Rajasthan utilization and sequential revenue ramp next quarter - check fixed-cost absorption and consolidated margin improvement. - RPL break-even next quarter - check whether ground-fleet and manpower costs are fully absorbed. - Karnataka collections - check government cash recovery and receivables normalization after approvals and procedural delays. - Maharashtra MRI rollout - check completion of remaining centers and initial utilization after staggered commissioning. ## Which stock lists is Krsnaa Diagnostics on? Krsnaa Diagnostics is on one of our India lists: 52 week high & low. [52 week high & low 52-week position: Near 52-week low](https://www.sectoralpha.in/52-week-high-stocks-india)

## Is Krsnaa Diagnostics profitable? Krsnaa Diagnostics Ltd earned ₹17.0 Cr of net profit in the Jun 2026 quarter, −19.0% on the same quarter a year earlier. Full-year FY26 profit was ₹101 Cr. That is 7.2% of the quarter's revenue. The same quarter a year earlier earned ₹21.0 Cr. For the full year, FY26 profit was ₹101 Cr (+29.5% on the year before). Why profit moved: revenue changed +22.3% on a year earlier and the margin moved −2.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed +20.0% and revenue +10.1%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Krsnaa Diagnostics make, and is it growing? Krsnaa Diagnostics Ltd reported ₹236 Cr of revenue in the Jun 2026 quarter, +22.3% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 34.8% a year on average. The last full year, FY26, came in at ₹773 Cr. The last four reported quarters add to ₹816 Cr. FY26 revenue was ₹773 Cr, +7.8% on the year before. Recent pace: the last four quarters grew +10.1% on average, against 34.8% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +10.3%, against +12.1% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +21.0%, against +27.8% a year (rolling over). ## How much of every ₹100 of sales does Krsnaa Diagnostics keep? Krsnaa Diagnostics Ltd's operating margin was 25.0% in the Jun 2026 quarter, 2.0 percentage points lower than the same quarter a year ago. Across 11 years it has been between −57.0% and 41.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −2.0 percentage points on the year while gross margin changed +3.3 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Krsnaa Diagnostics' profit turning into cash? Over the last 3 years, 108% of Krsnaa Diagnostics Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹143 Cr of operating cash against ₹101 Cr of profit. After ₹281 Cr of spending on assets, free cash was −₹138 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 108% of profit came in as cash: the cash cycle got 71 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 2.5× depreciation over three years. The next section checks what that spending is building. ## Where does Krsnaa Diagnostics' cash go? Krsnaa Diagnostics Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 140 days in FY26, up from 69 days in FY21. It spent ₹621 Cr on assets over the last 3 years. Customers take 140 days to pay, and stock sits for 54 days on average. At FY26 sales of ₹773 Cr, each day of that cycle ties up about ₹2.1 Cr, so roughly ₹296 Cr is tied up in the business at any time. FY26: customers took 140 days to pay and stock sat for 54 days, about 1.8 months of sales sitting as stock, for a full cycle of 140 days, longer than FY21's 69. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 54 days. Customers pay about 140 days after that. Suppliers are paid at 129 days. Together that makes the 140-day cycle. Spending on assets: ₹621 Cr over the last 3 years, against ₹253 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹208 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Krsnaa Diagnostics' P/E ratio, and how does it compare with its own history? Krsnaa Diagnostics Ltd's P/E is 16.2×, about the lowest it has ever been. Its usual P/E (the middle reading) is 28.6×, over 4.4 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +30.1% while the price moved −37.5%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 3 years the price moved −12.2% a year; about +14.6% a year came from earnings growth and about −26.8 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Krsnaa Diagnostics business getting better or worse? Krsnaa Diagnostics Ltd's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE steady at 13.4%; each line tells part of the story. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## How much does Krsnaa Diagnostics earn on its capital? Krsnaa Diagnostics Ltd earned a ROCE of 13% in FY26. That is up from a low of −65% in FY20. Its return on capital used (ROIC) is 4.0 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 13.1% net margin and 0.42× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 13.1% net margin × 0.42× asset turnover × 1.86× leverage (assets divided by equity) ≈ 10.2% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 8.0% − 12.0% = −4.0 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Krsnaa Diagnostics have too much debt? Krsnaa Diagnostics Ltd has total debt of ₹534 Cr against shareholder equity of ₹980 Cr as of Jun 2026, so its debt is 0.54× its equity. Year by year, that ratio went from 0.06 in FY22 to 0.54 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Krsnaa Diagnostics shareholding pattern? Domestic institutions cut their stake in Krsnaa Diagnostics Ltd by 1.4 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 14.5% of the company. Foreign institutions moved +0.2 points over the same period, to 3.8%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: −1.4 points over 8 quarters, to 14.5%; Foreign institutions: +0.2 points over 8 quarters, to 3.8%; Promoters: −0.1 points over 8 quarters, to 27.1%. Why the owners changed: domestic institutions drove it (−1.4 points). They reduced their stake. ## How far is Krsnaa Diagnostics from balance-sheet trouble? For Krsnaa Diagnostics Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Krsnaa Diagnostics rank in its industry? 49.6 out of 100, rank 8 of 9 in Diagnostics, with 81% of the evidence available. Krsnaa Diagnostics Ltd scores 49.6 out of 100 against the 9 companies it is compared with in Diagnostics, ranking 8. The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. The four parts add up to the total exactly: 13.7 + 9.1 + 18.9 + 7.9 = 49.6. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Krsnaa Diagnostics compared with? Krsnaa Diagnostics ranks 8 of 9 Diagnostics companies on the 4-Factor Sector Score, with 49.6 out of 100. 1. [One Global Service Provider Ltd](https://www.sectoralpha.in/stocks/one-global-service-provider-ltd) ONEGLOBAL · quiet · Most evidence points up · 81% evidence 70.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 100% · Profit 100% · Operating margin change 4 points · 88% evidence Capital efficiency 14.1/25 · ROCE 87% · Operating margin 19% · 100% evidence Valuation 18.5/20 · P/E 11.6× · PEG 0.45 · 100% evidence Relative strength 7.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -18.5% · 1 year 24.8% · 25% evidence · 0 of 5 weeks ahead Exact sum: 30.1 + 14.1 + 18.5 + 7.5 = 70.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Metropolis Healthcare Ltd](https://www.sectoralpha.in/stocks/metropolis-healthcare-ltd) METROPOLIS · turning · Evidence leans up · 96% evidence 64.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.7/35 · Revenue 21.8% · Profit 33.5% · Operating margin change 2 points · 88% evidence Capital efficiency 14.1/25 · ROCE 17.8% · Operating margin 25% · 100% evidence Valuation 13.3/20 · P/E 54.4× · PEG 1.08 · 100% evidence Relative strength 11.5/20 · Lead over its industry 3.2% · Lead over NIFTY 500 11.6% · 1 year 10.8% · 100% evidence · 4 of 12 weeks ahead Exact sum: 25.7 + 14.1 + 13.3 + 11.5 = 64.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Thyrocare Technologies Ltd](https://www.sectoralpha.in/stocks/thyrocare-technologies-ltd) THYROCARE · quiet · Evidence leans up · 100% evidence 60.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.0/35 · Revenue 22% · Profit 12.6% · Operating margin change 0 points · 100% evidence Capital efficiency 21.3/25 · ROCE 35.4% · Operating margin 33% · 100% evidence Valuation 12.6/20 · P/E 41.5× · PEG 1.1 · 100% evidence Relative strength 4.1/20 · Lead over its industry -6.7% · Lead over NIFTY 500 0.5% · 1 year -2% · 100% evidence · 7 of 12 weeks ahead Exact sum: 22 + 21.3 + 12.6 + 4.1 = 60 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Vijaya Diagnostic Centre Ltd](https://www.sectoralpha.in/stocks/vijaya-diagnostic-centre-ltd) VIJAYA · leader · Evidence leans up · 96% evidence 59.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 20.2% · Profit 23.8% · Operating margin change 4 points · 88% evidence Capital efficiency 16.4/25 · ROCE 20.5% · Operating margin 43% · 100% evidence Valuation 0.3/20 · P/E 79.4× · PEG 4.13 · 100% evidence Relative strength 18.7/20 · Lead over its industry 18.1% · Lead over NIFTY 500 26.8% · 1 year 46.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.1 + 16.4 + 0.3 + 18.7 = 59.5 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 5. [Suraksha Diagnostic Ltd](https://www.sectoralpha.in/stocks/suraksha-diagnostic-ltd) SURAKSHA · breaking out · Evidence leans up · 89% evidence 57.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.3/35 · Revenue 23% · Profit 9.4% · Operating margin change 2 points · 88% evidence Capital efficiency 11.7/25 · ROCE 17.3% · Operating margin 35% · 100% evidence Valuation 8.9/20 · P/E 46× · PEG 1.66 · 65% evidence Relative strength 17.2/20 · Lead over its industry 6.7% · Lead over NIFTY 500 15.6% · 1 year -0.5% · 100% evidence · 10 of 12 weeks ahead Exact sum: 19.3 + 11.7 + 8.9 + 17.2 = 57.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Dr Lal Pathlabs Ltd](https://www.sectoralpha.in/stocks/dr-lal-pathlabs-ltd) LALPATHLAB · leader · Evidence leans up · 96% evidence 56.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.4/35 · Revenue 14.3% · Profit 5% · Operating margin change 2 points · 88% evidence Capital efficiency 18.5/25 · ROCE 28% · Operating margin 31% · 100% evidence Valuation 9.3/20 · P/E 56.9× · PEG 1.29 · 100% evidence Relative strength 16.5/20 · Lead over its industry 15.5% · Lead over NIFTY 500 24.4% · 1 year 21.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 12.4 + 18.5 + 9.3 + 16.5 = 56.7 · What this means: Relative strength against the index is 24.4%, and revenue and profit growth are weak. 7. [3B Blackbio DX Ltd](https://www.sectoralpha.in/stocks/3b-blackbio-dx-ltd) 3BBLACKBIO · breaking out · Evidence leans up · 78% evidence 50.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.8/35 · Revenue 54.3% · Profit 14.7% · Operating margin change -27.8 points · 83% evidence Capital efficiency 16.6/25 · ROCE 25.5% · Operating margin 25.4% · 76% evidence Valuation 9.5/20 · P/E 20× · PEG n/a · 50% evidence Relative strength 9.0/20 · Lead over its industry -7% · Lead over NIFTY 500 1.2% · 1 year -5.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 15.8 + 16.6 + 9.5 + 9 = 50.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. Krsnaa Diagnostics Ltd this page KRSNAA · breaking out · Evidence leans down · 81% evidence 49.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.7/35 · Revenue 10.3% · Profit 21% · Operating margin change -2 points · 88% evidence Capital efficiency 9.1/25 · ROCE 12.7% · Operating margin 25% · 100% evidence Valuation 18.9/20 · P/E 16.8× · PEG 0.57 · 100% evidence Relative strength 7.9/20 · Lead over its industry n/a · Lead over NIFTY 500 -13.7% · 1 year -35.1% · 25% evidence · 1 of 12 weeks ahead Exact sum: 13.7 + 9.1 + 18.9 + 7.9 = 49.6 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 9. [Vimta Labs Ltd](https://www.sectoralpha.in/stocks/vimta-labs-ltd) VIMTALABS · quiet · Most evidence points down · 100% evidence 30.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 8.3/35 · Revenue 11.7% · Profit 2.5% · Operating margin change 0 points · 100% evidence Capital efficiency 15.7/25 · ROCE 25.2% · Operating margin 34% · 100% evidence Valuation 4.6/20 · P/E 26.6× · PEG 2.75 · 100% evidence Relative strength 1.5/20 · Lead over its industry -12.6% · Lead over NIFTY 500 -5.4% · 1 year -33.2% · 100% evidence · 8 of 12 weeks ahead Exact sum: 8.3 + 15.7 + 4.6 + 1.5 = 30.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Diagnostics](https://www.sectoralpha.in/sectors/diagnostics), all 9 compared on one page. ## Which companies are close to Krsnaa Diagnostics in size? Krsnaa Diagnostics is the 7th largest of 9 Diagnostics companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Metropolis Healthcare, Thyrocare Technologies, Vimta Labs and Suraksha Diagnostic. Just below it: 3B Blackbio DX and One Global Service Provider. ### Diagnostics companies close in size

1. [Metropolis Healthcare Ltd](https://www.sectoralpha.in/stocks/metropolis-healthcare-ltd) ₹11,320 crore
2. [Thyrocare Technologies Ltd](https://www.sectoralpha.in/stocks/thyrocare-technologies-ltd) ₹7,263 crore
3. [Vimta Labs Ltd](https://www.sectoralpha.in/stocks/vimta-labs-ltd) ₹2,168 crore
4. [Suraksha Diagnostic Ltd](https://www.sectoralpha.in/stocks/suraksha-diagnostic-ltd) ₹1,648 crore
5. Krsnaa Diagnostics Ltd ₹1,634 crore
6. [3B Blackbio DX Ltd](https://www.sectoralpha.in/stocks/3b-blackbio-dx-ltd) ₹1,112 crore
7. [One Global Service Provider Ltd](https://www.sectoralpha.in/stocks/one-global-service-provider-ltd) ₹858 crore

[All 9 Diagnostics companies, largest first](https://www.sectoralpha.in/sectors/diagnostics#all-companies)

### Companies close in size in other industries

1. [Suraksha Diagnostic Ltd](https://www.sectoralpha.in/stocks/suraksha-diagnostic-ltd) ₹1,648 crore · Diagnostics
2. [I G Petrochemicals Ltd](https://www.sectoralpha.in/stocks/i-g-petrochemicals-ltd) ₹1,636 crore · Chemicals - Organic - Maleic Anhydride
3. Krsnaa Diagnostics Ltd ₹1,634 crore
4. [Disa India Ltd](https://www.sectoralpha.in/stocks/disa-india-ltd) ₹1,629 crore · Capital Goods - Engineering Heavy
5. [Hindusthan Insulators & Industries Ltd](https://www.sectoralpha.in/stocks/hindusthan-insulators-industries-ltd) ₹1,626 crore · Electric Equipment - General

## What else do people ask about Krsnaa Diagnostics? ### What is Krsnaa Diagnostics's share price today? Krsnaa Diagnostics Ltd's share price is ₹485.80, −37.5% over the past year. The whole company is worth ₹1,575 Cr on the market. It is at its lowest price of the past 52 weeks (range ₹486 to ₹817), 17.6% below its 200-day average. The price has been falling for 45 weeks (as of 3 November 2026). ### What were Krsnaa Diagnostics's latest quarterly results? Krsnaa Diagnostics Ltd reported revenue of ₹236 Cr and net profit of ₹17.0 Cr for the Jun 2026 quarter. Revenue rose 22.3% and profit fell 19.0% compared with a year earlier. Earnings per share were ₹5.10. The operating margin was 25.0%, 2.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Krsnaa Diagnostics's market cap? Krsnaa Diagnostics Ltd's market capitalisation is ₹1,575 Cr at a share price of ₹485.80. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Krsnaa Diagnostics performing? Krsnaa Diagnostics Ltd's share price has been falling for 45 weeks. In its latest quarter, revenue rose 22.3% and profit fell 19.0% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 1 week running (as of 3 November 2026). ### Will Krsnaa Diagnostics's share price go up? This page does not forecast Krsnaa Diagnostics Ltd's share price. What it shows instead: the share price is ₹485.80, and it has been falling for 45 weeks. Its P/E of 16.2× is higher than 0% of its own last 4 years (as of 3 November 2026). ### Who owns Krsnaa Diagnostics? Promoters own 27.1% of Krsnaa Diagnostics Ltd, foreign institutions 3.8%, domestic institutions 14.5% and the public 54.5% (latest quarter). The biggest change over the last two years: Domestic institutions cut their stake by 1.4 percentage points over 8 quarters (as of 3 November 2026). ### Where is Krsnaa Diagnostics in its business cycle? Krsnaa Diagnostics Ltd's FY26 operating margin was 27.0%, against a 11-year range of −57.0% to 41.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 25.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Krsnaa Diagnostics story? The main question: yearly earnings per share moved +30.1% while the share price moved −37.5%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Krsnaa Diagnostics a stock worth studying right now? What the numbers show: Krsnaa Diagnostics Ltd's P/E is near the low end of its own history, higher than only 0% of past readings, and its quarterly results are still getting worse. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Krsnaa Diagnostics share price forecast for 2026? What management itself guided: Rajasthan revenue expected to double in July to September 2026; FY27 clear visibility ₹100-150 crore and steady-state ₹150-175 crore; earlier ₹200-250 crore aspiration retained. ## Lists

- 52 week high & low: https://www.sectoralpha.in/52-week-high-stocks-india

This is research, not advice. We’re not SEBI-registered.